Why Radius Health Stock Is Getting Pummeled Today
The stock of Radius Health (NASDAQ: RDUS) is tumbling today after the company presented follow-up data for its experimental breast cancer treatment. Investors disappointed with the biopharmaceutical company's update pushed the stock 44.3% lower as of 12:44 p.m. ET on Wednesday.
Back in October, Radius stock shot up when the company told investors its elacestrant, a potential first-in-class selective estrogen receptor degrader (SERD), significantly reduced the risk of disease progression for advanced-stage breast cancer patients during the phase 3 Emerald trial.
Image source: Getty Images.
Source Fool.com
